L

Lipocine
D

LPCN

4.91000
USD
0.05
(1.03%)
Market Closed
Volume
494
EPS
-2
Div Yield
-
P/E
-7
Market Cap
26,258,385
Related Instruments
    A
    ACST
    0
    (0%)
    0.000000 USD
    A
    AMRN
    -0.03370
    (-7.04%)
    0.44500 USD
    A
    AXSM
    -3.970
    (-4.37%)
    86.870 USD
    E
    EVOK
    -0.04000
    (-0.79%)
    5.05000 USD
    F
    FGEN
    0.06830
    (16.77%)
    0.47550 USD
    V
    VKTX
    0.045
    (0.11%)
    42.315 USD
    More
News

Title: Lipocine

Sector: Healthcare
Industry: Biotechnology
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.